Please login to the form below
Novo Holdings
This page shows the latest Novo Holdings news and features for those working in and with pharma, biotech and healthcare.
Muna raises $73m to advance neurodegenerative disease-focused small molecule pipeline
Backed by Novo Holdings, Muna is focused on the development of novel small molecule therapeutics targeting neurodegenerative diseases including Alzheimer’s, frontotemporal dementia and Parkinson’s. ... Muna was founded in 2020 by Simon Glerup and his
Latest news
-
Oxford Biomedica gets £53m cash injection from Novo venture arm
John Dawson. “We are delighted that Novo Holdings has become a shareholder in Oxford Biomedica,” said John Dawson, chief executive of Oxford Biomedica. ... Novo Holdings is a well-known and highly regarded long-term investor with significant
-
UK biotech bags €1.5m grant for new antibiotic class
The cash injection comes from the Novo Holdings REPAIR Impact Fund, a 135m investment vehicle set up by Danish drugmaker Novo Nordisk last year specifically to advance research into new drugs ... Among Novo fund’s other investments, US biotech Entasis
-
Daily brief: Global Blood confident of sickle cell success, Breathalyser wins engineering award, Swiss biotech raises funds
Novo Holdings financed the company, and together with an earlier boost of CHF 20m, the group’s total has reached CHF 40m.
-
Novo launches $165m antimicrobial resistance initiative
The REPAIR fund is the brainchild of Novo Holdings, the major shareholder in the Novo Group companies and will focus on priority pathogens, which the World Health Organization (WHO) defines as ... Kasim Kutay, chief executive officer of Novo Holdings,
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
The threat of antimicrobial resistance
These initiatives have been recently joined by a $165m ‘REPAIR’ fund from Novo Holdings, as an investment in companies involved in discovery and early-stage development of therapies to combat antimicrobial
-
Deal Watch table for February 2014
2. and CKD. 3. 198. Zosano (formerly Macroflux) / Novo Nordisk. ... UDG subsidiaries : The Specials Laboratory Holdings, Craig &Hayward, Arjun Products.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Lars Rebien Sørensen becomes chairman of Novo Holdings
He will take up the new role 1 July. Former Novo Nordisk CEO Lars Rebien Sørensen has been appointed as Novo Holdings’ new chairman. ... He said: “In recent years, Novo Holdings has significantly increased its investments and influence in the global
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Novartis receives EC approval for Cosentyx in hidradenitis suppurativa
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Pfizer’s antibiotic combination shows promise in treating multi-drug resistant infections
- Sanofi's frexalimab shows promise in relapsing forms of MS
- EMA recommends revoking marketing authorisation for Novartis’ sickle cell disease drug
- Pfizer’s RSV vaccine approved by FDA for older adults
- Navigating patients step by step on their clinical trial journey
- Innovative Trials responds to national recommendations to tackle UK clinical trial decline
- AstraZeneca shares positive phase 3 results for Tagrisso in lung cancer
- BMS presents positive four-year results for Opdivo combination in lung cancer
- Tuberculosis – why it remains a major global public health challenge
- Whitepaper: Closing the gap with compelling healthcare communications
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Tuberculosis – why it remains a major global public health challenge
- Innovative collaboration is required to address the major public health challenges around TB and expedite drug development...
- Whitepaper: Closing the gap with compelling healthcare communications
- Want to learn how to close the distance between a person’s current health and their healthiest possible self?...
- Healing the Healers
- Because if we do not heal the healers, who is going to heal us?...
